Shopping Cart
- Remove All
Your shopping cart is currently empty
Tavilermide
😃Good
Catalog No. T17000Cas No. 263251-78-1
Alias MIM-D3, MIMD3
Tavilermide (MIM-D3) is a selective TrkA agonist, a cyclic mimetic, which can be used to study dry keratoconjunctivitis and dry eye syndrome.
Tavilermide
😃Good
Purity: 98.98%
Catalog No. T17000Alias MIM-D3, MIMD3Cas No. 263251-78-1
Tavilermide (MIM-D3) is a selective TrkA agonist, a cyclic mimetic, which can be used to study dry keratoconjunctivitis and dry eye syndrome.
| Pack Size | Price | Availability | Quantity |
|---|---|---|---|
| 5 mg | $447 | 6-8 weeks | |
| 25 mg | $1,520 | 6-8 weeks | |
| 50 mg | $1,980 | 6-8 weeks | |
| 100 mg | $2,500 | 6-8 weeks |
Bulk & Custom
Add to Cart
Questions
View MoreInhibitors Related to "Tavilermide"
Amitriptyline hydrochloride
Tryptizol, Domical, Annoyltin, Amitriptyline HCl
T0678549-18-8
Amitriptyline hydrochloride (Annoyltin) is the hydrochloride salt of the tricyclic dibenzocycloheptadiene amitriptyline with antidepressant and antinociceptive activities.
5-HT ReceptorAChRAdrenergic ReceptorHistamine ReceptorNorepinephrineSerotonin TransporterSigma receptorSodium ChannelTrk receptor
- $45
Size
QTY
GW 441756
T6052504433-23-2
GW 441756 is a specific Tropomyosin-related kinase A (TrkA) inhibitor with an IC50 value of 2 nM.
- $51
Size
QTY
Larotrectinib sulfate
LOXO-101 sulfate, LOXO-101 (sulfate), ARRY-470 (sulfate)
T68801223405-08-0
Larotrectinib sulfate (LOXO-101 sulfate) is an oral active and specific ATP-competitive inhibitor of tropomyosin receptor kinases (TRK).
- $33
Size
QTY
Diosmetin
Cited
Luteolin 4-methyl ether
T1704520-34-3
Diosmetin (Luteolin 4-methyl ether) has been found to act as a weak TrkB receptor agonist.
- $34
Size
QTY
Cited7,8-Dihydroxyflavone
7,8-DHF
T281638183-03-8
7,8-Dihydroxyflavone (7,8-DHF) is a naturally-occurring flavone and exist in Tridax procumbens, Godmania aesculifolia, and primula tree leaves.
- $30
Size
QTY
SP600125
Cited
Pyrazolanthrone, Nsc75890, JNK Inhibitor II, 1PMV
T3109129-56-6
SP600125 (JNK Inhibitor II) is a JNK inhibitor that inhibits JNK1, JNK2, and JNK3 (IC50=40/40/90 nM) with oral potency, reversibility, and ATP-competitive properties. SP600125 inhibits autophagy and induces apoptosis.
- $41
Size
QTY
CitedN-Acetyl-5-hydroxytryptamine
O-Demethylmelatonin, Normelatonin, N-Acetylserotonin
T13541210-83-9
N-Acetyl-5-hydroxytryptamine (O-Demethylmelatonin) , also known as Normelatonin, is the immediate precursor of melatonin. It is produced from serotonin by the enzyme aralkylamine N-acetyltransferase and is converted to melatonin by acetylserotonin O-methyltransferase. It can potently activate TrkB receptor.
- $32
Size
QTY
Selitrectinib Cited
LOXO-195
T74352097002-61-2
Selitrectinib (LOXO-195) is a potent and selective inhibitor of the receptor tyrosine kinases(TRK)( TrkA and TrkC with IC50s of 0.6 and <2.5 nM, respectively).
- $34
Size
QTY
CitedALE-0540
ALE0540
T9292234779-34-1In house
ALE-0540 is a nonpeptidic heterocyclic molecule that inhibits the binding of NGF to p75 and TrkA, as well as signal transduction and biological responses mediated by TrkA receptors.
- $30
Size
QTY
Sitravatinib Cited
MGCD516, MG516
T43491123837-84-2
Sitravatinib (MGCD516) is an inhibitor targeting multiple RTKs involved in driving sarcoma cell growth, including c-Met, c-Kit, PDGFRα/β, PDGFR, and Axl.
- $47
Size
QTY
CitedCG 428
T412242412055-93-5In house
CG 428 is a potent tropomyosin receptor Kinase (TRK) Degrader (uSMITETM) with a DC50 of 0.36 nM. CG 428 comprises an analog of the pan-TRK inhibitor GNF-8625 joined by a linker to the cereblon E3 ligase ligand pomalidomide. CG 428 shows selectivity for TRKA over TRKC and TRKB with Kds of 1nM, 4.2 nM, and 28 nM. CG 428 inhibits the growth of KM12 colon cancer cells with an IC50 of 2.9 nM.
- $178
Size
QTY
LM22A-4
T756837988-18-4
LM22A-4 is a brain-derived neurotrophic factor (BDNF) mimetic and agonist of the receptor tropomyosin-related kinase B (TrkB; IC50 : 47 nM in a fluorescence anisotropy assay)
- $39
Size
QTY
Select Batch
Purity:98.98%
Contact us for more batch information
Resource Download
Product Introduction
Bioactivity
Chemical Properties
| Description | Tavilermide (MIM-D3) is a selective TrkA agonist, a cyclic mimetic, which can be used to study dry keratoconjunctivitis and dry eye syndrome. |
| In vitro | Tavilermide, a tyrosine kinase TrkA receptor agonist, is a protease-stabilized cyclic peptide mimetic that has been shown to be a partial TrkA receptor agonist for the treatment of dry eye. Tavilermide exhibits activity similar to that of nerve growth factor (NGF), but does not bind to the p75NTR receptor, and enhances the effects of suboptimal concentrations of effects of NGF. [1] |
| Alias | MIM-D3, MIMD3 |
| Molecular Weight | 580.54 |
| Formula | C24H32N6O11 |
| Cas No. | 263251-78-1 |
| Smiles | O=C1C=2C(=CC=C(N(=O)=O)C2)OCC[C@@H](C(NCC(O)=O)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCC(O)=O)N1 |
| Relative Density. | 1.341 g/cm3 (Predicted) |
Storage & Solubility Information
| Storage | store at low temperature | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice. | |||||||||||||||||||||||||||||||||||
| Solubility Information | NH4OH: 30 mg/mL(51.68 mM), Adjust pH with NH4OH and sonication is recommended. H2O: 1 mg/mL(1.72 mM), Sonication is recommended. | |||||||||||||||||||||||||||||||||||
Solution Preparation Table | ||||||||||||||||||||||||||||||||||||
H2O/NH4OH
NH4OH
| ||||||||||||||||||||||||||||||||||||
Calculator
In Vivo Formulation Calculator (Clear solution)
Please enter your animal experiment information in the following box and click Calculate to obtain the mother liquor preparation method and in vivo formula preparation method:
For example, your dosage is 10 mg/kg Each animal weighs 20 g, and the dosage volume is 100 μL . A total of 10 animals were administered, and the formula you used is 5% 
DMSO+30% PEG300+5% Tween 80+60% ddH2O. So your working solution concentration is 2 mg/mL。Mother liquor preparation method: 2 mg of drug dissolved in 50 μL DMSO (mother liquor concentration of 40 mg/mL), if you need to configure a concentration that exceeds the solubility of the product, please contact us first.
(mother liquor concentration of 40 mg/mL), if you need to configure a concentration that exceeds the solubility of the product, please contact us first.Preparation method for in vivo formula: Take 50 μL DMSO main solution, add 300 μLPEG300 mix well and clarify, then add 50 more μL Tween 80, mix well and clarify, then add 600 more μLddH2O mix well and clarify
main solution, add 300 μLPEG300 mix well and clarify, then add 50 more μL Tween 80, mix well and clarify, then add 600 more μLddH2O mix well and clarifyFor Reference Only. Please develop an appropriate dissolution method based on your laboratory animals and route of administration.
Dose Conversion
You can also refer to dose conversion for different animals. More Dose Conversion
Tech Support
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc
Preview
Related Tags: buy Tavilermide | purchase Tavilermide | Tavilermide cost | order Tavilermide | Tavilermide chemical structure | Tavilermide in vitro | Tavilermide formula | Tavilermide molecular weight
- TOP
Feedback
Hello! How can I help you today? 
Copyright © 2015-2024 TargetMol Chemicals Inc. All Rights Reserved.